Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "VAI"

1899 News Found

Supriya Lifescience receives USFDA EIR with VAI classification for Maharashtra API facility
News | April 22, 2026

Supriya Lifescience receives USFDA EIR with VAI classification for Maharashtra API facility

Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States


Max Institute of Cancer Care, Vaishali showcases advanced oncology technologies at ONCO-CON 2026
Hospitals | April 14, 2026

Max Institute of Cancer Care, Vaishali showcases advanced oncology technologies at ONCO-CON 2026

The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care


Granules Life Sciences receives VAI Classification for Shamirpet facility
News | March 31, 2026

Granules Life Sciences receives VAI Classification for Shamirpet facility

The inspection is now closed, and no regulatory action has been recommended


APL Healthcare’s Unit-IV classified as VAI by the USFDA
News | March 14, 2026

APL Healthcare’s Unit-IV classified as VAI by the USFDA

This inspection is now closed


Zota Health Care expands Davaindia network to 2,502 stores nationwide
News | February 13, 2026

Zota Health Care expands Davaindia network to 2,502 stores nationwide

The surge has been driven largely by COCO stores, with 755 COCO and 165 FOFO outlets added this fiscal year


Merck wins key EU backing to expand use of PAH Drug WINREVAIR
News | December 13, 2025

Merck wins key EU backing to expand use of PAH Drug WINREVAIR

WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states


Biocon Biologics' Drug Substance Facility in Bengaluru cassified as VAI
Drug Approval | November 29, 2025

Biocon Biologics' Drug Substance Facility in Bengaluru cassified as VAI

This relates to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States


Glenmark Pharma gets VAI from FDA for Monroe facility
Drug Approval | November 27, 2025

Glenmark Pharma gets VAI from FDA for Monroe facility

The positive outcome clears the way for Glenmark to resume commercial manufacturing at the site


Merck’s WINREVAIR shows promise in phase 2 study for hard-to-treat pulmonary hypertension
Clinical Trials | November 21, 2025

Merck’s WINREVAIR shows promise in phase 2 study for hard-to-treat pulmonary hypertension

The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction